Table 1.
Results of the in vitro antimicrobial susceptibility testing
| |
0.008 |
0.015 |
0.03 |
0.06 |
0.12 |
0.25 |
0.5 |
1 |
2 |
4 |
8 |
16 |
32 |
64 |
128 |
ECOFF |
CLSI CBP |
MIC90 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | mg/L | (mg/L) | (mg/L) | ||
| AMC |
|
|
|
2 |
43 |
44 |
|
|
|
|
1 |
|
|
|
|
ND |
≥ 32/16 |
0.25 |
| AMP |
|
|
|
1 |
20 |
68 |
|
1 |
|
|
|
|
|
|
|
≤ 0.25 |
≥ 8 |
0.25 |
| CEF |
|
|
|
|
1 |
53 |
35 |
|
|
1 |
|
|
|
|
|
ND |
≥ 32 |
0.5 |
| CFP |
|
|
|
|
1 |
44 |
44 |
|
1 |
|
|
|
|
|
|
≤ 0.125 |
ND |
0.5 |
| CFQ |
|
|
1 |
24 |
65 |
|
|
|
|
|
|
|
|
|
|
ND |
ND |
0.12 |
| CHL |
|
|
|
|
|
|
|
2 |
83 |
4 |
1 |
|
|
|
|
ND |
≥16 |
2 |
| CLI |
|
|
10 |
80 |
|
|
|
|
|
|
|
|
|
|
|
≤0.5 |
ND |
0.06 |
| CTX |
|
|
1 |
52 |
35 |
1 |
|
1 |
|
|
|
|
|
|
|
≤ 0.125 |
ND |
0.12 |
| ENR |
|
|
1 |
|
|
|
5 |
75 |
8 |
|
|
|
|
|
|
ND |
ND |
1 |
| ERY |
|
2 |
14 |
74 |
|
|
|
|
|
|
|
|
|
|
|
≤ 0.25 |
≥ 1 |
0.06 |
| GEN |
|
|
|
|
|
|
1 |
|
|
|
1 |
15 |
71 |
2 |
|
ND |
≥ 16 |
32 |
| OXA |
|
1 |
|
|
|
4 |
85 |
|
|
|
|
|
|
|
|
ND |
ND |
0.5 |
| PEN |
|
1 |
|
39 |
48 |
|
1 |
|
1 |
|
|
|
|
|
|
ND |
≥4 |
0.12 |
| PIRL |
|
|
|
3 |
80 |
7 |
|
|
|
|
|
|
|
|
|
ND |
≥4 |
0.12 |
| Q-D |
|
|
|
|
1 |
6 |
83 |
|
|
|
|
|
|
|
|
ND |
ND |
0.5 |
| SPI |
|
|
|
1 |
|
84 |
4 |
|
|
|
|
|
|
|
|
ND |
ND |
0.25 |
| SXT |
|
|
28 |
57 |
3 |
1 |
|
|
|
|
|
|
|
|
|
ND |
≥ 76 |
0.06 |
| TET |
|
|
|
|
|
26 |
31 |
1 |
|
|
|
|
12 |
19 |
|
≤ 1.0 |
≥ 8 |
64 |
| TIL |
|
|
|
|
|
2 |
1 |
|
4 |
83 |
|
|
|
|
|
ND |
ND |
4 |
| TUL |
|
|
|
|
1 |
1 |
78 |
10 |
|
|
|
|
|
|
|
ND |
ND |
1 |
| TYL |
|
|
|
|
1 |
3 |
56 |
30 |
|
|
|
|
|
|
|
ND |
ND |
1 |
| VAN |
|
|
|
|
|
|
82 |
8 |
|
|
|
|
|
|
|
≤1.0 |
ND |
0.5 |
| XNL | 1 | 5 | 83 | 1 | ND | ≥ 8 | 0.25 |
ECOFF-epidemiological cut-off value (retrieved from the European Committee on Antimicrobial Susceptability Testing), CLSI CBP-CLSI M31-A3 veterinary clinical breakpoint for resistance, MIC90-Minimum Inhibitory Concentration required to inhibit the growth of 90% of organisms, ND-not determined, GBS-Group B Streptococcus agalactiae, AMC-Amoxicillin-clavulanic acid (2:1 ratio), AMP-Ampicillin, CEF – Cephalothin, CFP - Cefoperazone, CFQ – Cefquinome, CHL – Chloramphenicol, CLI – Clindamycin, CTX – Cefotaxime, ENR – Enrofloxacin, ERY – Erythromycin, GEN – Gentamicin, OXA – Oxacillin + 2% NaCl, PEN – Penicillin, PIRL – Pirlimycin, Q-D - Quinupristin/Dalfopristin, SPI – Spiramycin, SXT - Trimethoprim/Sulfamethoxazole, TET – Tetracycline, TIL – Tilmicosin, TUL – Tulathromycin, TYL – Tylosin, VAN – Vancomycin, XNL – Ceftiofur.